Drug Patents owned by Mirum
1. List of Livmarli drug patents
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(8 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(9 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(16 years from now) | |
| US11497745 | MIRUM | NA |
Feb, 2040
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
| Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 2025-09-29
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
More Information on Dosage
LIVMARLI family patents
40
United States
10
Japan
10
European Union
9
Australia
8
Korea, Republic of
7
China
6
Israel
6
Singapore
5
Canada
5
Mexico
5
Brazil
4
EA
4
South Africa
2
Hong Kong
2
Spain
1
Portugal
1
Poland
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic